P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to investigate the effects of high-dose octreotide on
flushing, diarrhea, and quality of life in patients whose disease-related symptoms are
inadequately controlled by the maximum approved dose of octreotide LAR.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute